Page last updated: 2024-08-21

dihydroergotamine and pazopanib

dihydroergotamine has been researched along with pazopanib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Almonacid, DE; Bascur, JP; González-Nilo, FD; Juritz, EI1

Reviews

1 review(s) available for dihydroergotamine and pazopanib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for dihydroergotamine and pazopanib

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Molecular diagnosis & therapy, 2018, Volume: 22, Issue:3

    Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Dasatinib; Dihydroergotamine; Enzyme Inhibitors; Epirubicin; Gene Expression; High-Throughput Screening Assays; Humans; Indazoles; Indoles; Isocitrate Dehydrogenase; Molecular Docking Simulation; Mutation; Phenylcarbamates; Pivampicillin; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Protein Multimerization; Pyrimidines; Sulfonamides; Thermodynamics; Tosyl Compounds; User-Computer Interface

2018